Watchlist Price Alert

Baxter International Inc. (BAX)

NYSE: BAX · Real-Time Price · USD

30.66

-0.01 (-0.03%)

At close: May 02, 2025, 3:59 PM

30.21

-1.45%

After-hours: May 02, 2025, 07:26 PM EDT

-0.03% (1D)

Bid	29.71
Market Cap	15.72B
Revenue (ttm)	11.89B
Net Income (ttm)	-366M
EPS (ttm)	-0.58
PE Ratio (ttm)	-52.85
Forward PE	11.22
Analyst	Hold

Ask	30.71
Volume	3,254,956
Avg. Volume (20D)	5,022,804
Open	31.14
Previous Close	30.67
Day's Range	30.23 - 31.25
52-Week Range	26.25 - 40.49
Beta	0.65

About BAX

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nu...

Sector Healthcare

IPO Date Oct 27, 1981

Employees 38,000

Stock Exchange NYSE

Ticker Symbol BAX

Website https://www.baxter.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for BAX stock is "Hold." The 12-month stock price forecast is $38, which is an increase of 23.96% from the latest price.

Stock Forecasts

Earnings Surprise

Baxter International has released their quartely earnings on May 1, 2025:

Revenue of $2.63B exceeds estimates by $35M, with 5.42% YoY growth.

EPS of 0.62 exceeds estimates by 0.14, with -4.62% YoY decline.

Why Price Moved

3 days ago

-1.6%

BAX stock has given up its prior gain. Baxter Inte... Unlock content with Pro Subscription

4 days ago

-1.6%

Baxter International shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

News

4 days ago · seekingalpha.com

Baxter International Inc. (BAX) Q1 2025 Earnings Call Transcript

Baxter International Inc. (NYSE:BAX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President and Chief Investor Relations Officer Brent Sh...

4 days ago · zacks.com

BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y

Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts.

4 days ago · benzinga.com

Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps

On Thursday, Baxter International Inc. BAX reported a first-quarter 2025 adjusted EPS of 62 cents, beating the management guidance of 47 to 50 cents and the Wall Street estimate of 48 cents.

3 days ago · zacks.com

Baxter (BAX) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to ...

3 days ago · reuters.com

Baxter tops quarterly estimates on strong demand for medical devices

Medical products maker Baxter International on Thursday beat Wall Street estimates for first-quarter revenue and profit, helped by the robust demand for its intravenous (IV) solutions and patient-moni...

3 days ago · businesswire.com

Baxter Reports First-Quarter 2025 Results

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2025. “Our solid performance in the first quarter of 20...

5 days ago · zacks.com

MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.

6 days ago · businesswire.com

Baxter to Present at Bank of America Securities 2025 Health Care Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Jo...

1 week ago · zacks.com

Will BAX's Q1 Earnings Improve Following Transformation Completion?

Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.

3 weeks ago · businesswire.com

Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery

VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature st...

Load More News